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The psoriatic shift induced by interleukin 17 is promptly reverted by a specific anti-IL-17A agent in a three-dimensional organotypic model of normal human skin culture
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Interleukin 17A (IL-17A), mainly produced by the T helper subclass Th17, plays a key role in the psoriatic
plaque formation and progression. The clinical effectiveness of anti-IL-17A agents is documented, but the early
and specific mechanisms of their protection are not identified yet. The challenge of the present study is to inves-
tigate the possible reversal exerted by a specific anti-IL-17A agent on the psoriatic events induced by IL-17A
in a three-dimensional organotypic model of normal human skin. Bioptic skin fragments obtained after aesthet-
ic surgery of healthy women (n=5) were incubated with i) IL-17A biological inhibitor (anti-IL-17A), ii) IL-
17A, iii) a combination of IL-17A and its specific IL-17A biological inhibitor (COMBO). A Control group was
in parallel cultured and incubation lasted for 24 and 48 h epidermal-side-up at the air-liquid interface. All sub-
jects were represented in all experimental groups at all considered time-points. Keratinocyte proliferation and
the presence of epidermal Langerhans cells were quantitatively estimated. In parallel with transmission electron
microscopy analysis, immunofluorescence studies for the epidermal distribution of keratin (K)10, K14, K16,
K17, filaggrin/occludin, Toll-like Receptor 4, and Nuclear Factor kB were performed. IL-17A inhibited cell
proliferation and induced K17 expression, while samples incubated with the anti-IL-17A agent were compara-
ble to controls. In the COMBO group the IL-17A-induced effects were almost completely reverted. Our study,
for the first time, elucidates the most specific psoriatic cellular events that can be partially affected or complete-
ly reverted by a specific anti-IL-17A agent during the early phases of the plaque onset and progression. On the
whole, this work contributes to expand the knowledge of the psoriatic tableau.
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Introduction
A complex and fascinating interplay among circulating
cytokines and different epidermal cytotypes leads to the formation
and to the progression of the psoriatic plaque. Most of the literature
has produced great information concerning T cell maturation and
modifications induced by interleukin-17 (IL-17), especially
regarding the specific pathogenic role of IL-17A isoform in psori-
asis.1 Much fewer data take into account the early epidermal injury
of IL-17A on the physical/immune epidermal barrier and the termi-
nal differentiation, as well as the possible recovery after adminis-
tration of anti-IL-17A.2,3 Although the clinical effectiveness of
anti-IL-17A agents is widely reported, the cellular mechanisms
underlying their protection are not identified yet. A good possibil-
ity to complete this tableau springs from the three-dimensional
(3D) organotypic model of normal human skin culture. This exper-
imental approach is a simple and very clean setting allowing the
study of the sharp epidermal changes induced by a stimulus, in this
case IL-17A, with any involvement of neither blood nor lymphatic
supply. Keratinocytes (KCs) and Langerhans cells (LCs) are the
two main epidermal cytotypes implicated in organizing a fast and
specific response to overcome the possible insult.4,5 Epidermal
KCs are characterized by an abundant cytoplasmic network of ker-
atin (K) intermediate filaments, ranging from 10% of total proteins
in the basal proliferative layer to 70% in the uppermost epidermal
layers, thus reflecting a dynamic regulation through the differenti-
ation process.6 During this process, K5/K14 are typically
expressed in the proliferative basal compartment, while K1/K10 in
the suprabasal differentiating layers. Keratins have been recog-
nized as regulators of many cell functions and as mediators of the
epidermal integrity maintenance after a stress.7 A mechanical skin
injury significantly affects keratin expression.8 In particular, K16
and K17 were indicated as “psoriatic keratins” in the differentiated
epidermal layers as they are associated with epidermal hyperpro-
liferation. 9 Simultaneously, further processes possibly occur with-
in the “injured” epidermis to promote a defense response: epider-
mal LCs can be recruited, accumulated, and finally activated for
the later migration. In parallel, a specific expression of Toll-like
Receptors (TLRs) can follow, thus enhancing the binding with spe-
cific ligands, with the consequent activation of the transcription
factor Nuclear Factor kB (NFkB) and translocation from the cyto-
plasm to the nucleus.10
The challenge of the present study is to investigate the effects
of an IgG1 monoclonal antibody anti-IL-17A (anti-IL-17A agent)
on the morphological psoriatic events, directly induced by IL-17A,
in the 3D organotypic model of normal human skin culture, previ-
ously standardized in our lab.4,5,11-13 Specific attention was payed to
keratin expression and to the integrity of the physical/immune epi-
dermal barrier, as evaluated by immunofluorescence. Moreover,
the ultrastructural analysis allowed evaluating morphological fea-
tures of activated LCs and, again by immunofluorescence, TLR4
expression was taken into account.
Materials and Methods
3D organotypic model of normal human skin culture 
Human skin samples were obtained from plastic aesthetic sur-
gery of abdominal or mammary regions of healthy nonsmoking
20- to 40-year-old women (n=5); written informed consent was
obtained from all subjects. Immediately after excision, the biopsies
were reduced into 0.5- to 1-cm2 fragments using a sterile scalpel.
All fragments were placed epidermal-side-up at the air-liquid inter-
face in a Transwell system (Costar, Corning, NY, USA) and main-
tained at 37°C and 5% CO2 overnight, in order to reduce the acute
effects of surgery. Samples were cultured in Dulbecco’s modified
Eagle’s culture medium (Euroclone, Milan, Italy) containing 10%
fetal bovine serum (Invitrogen, Life Technologies Ltd., Paisley,
UK) supplemented with penicillin/streptomycin, amphotericin B
and glutamine (Sigma-Aldrich, St. Louis, MO, USA). No hydro-
cortisone was added to avoid an anti-inflammatory activity on epi-
dermal KCs as previously described.4 In order to evaluate KC pro-
liferation, 3 h prior to the end of the experiment the culture medi-
um was enriched with 400 µmol 5-bromo-2’-deoxyuridine (BrdU),
a nonradioactive analogue of thymidine selectively incorporated
into the DNA of S-phase cells. Specimens were further divided in
three different groups which were added 2 µg/ml of anti-IL-17A
agent (anti-IL-17A group), 50 ng/mL IL-17A (IL-17A group) or a
combination of both (COMBO group). Samples were harvested 24
(T24) and 48 h (T48) after cytokine addition and were processed
in parallel for light and transmission electron microscopy. Control
samples (CTRL) were cultured in normal medium. All bioptic
samples were represented at each time point and in all experimen-
tal groups.
Light microscopy analysis
All specimens were fixed in 4% paraformaldehyde buffered
with 0.1 M phosphate-buffered saline (PBS) pH 7.4 for 5 h at room
temperature (RT), dehydrated in an ascending scale of ethanols and
paraffin embedded. Five-micrometer-thick serial sections were
obtained using a rotary microtome (RM2245; Leica Microsystems
GmbH, Wetzlar, Germany). At least 40 slides/sample were obtained
and five non-consecutive slides for each sample were stained with
hematoxylin and eosin to observe the morphological features.
Transmission electron microscopy analysis
For transmission electron microscopy analysis, specimens
(2x2 mm) were immersion-fixed in 3% glutaraldehyde diluted in
0.1 M Sorensen’s phosphate buffer (pH 7.4) overnight at 4°C. Each
sample was then washed with Sorensen’s phosphate buffer (3
washes of 30 min each), post-fixed in 1% osmium tetroxide in
Sorensen’s buffer, dehydrated through an ascending scale of ace-
tone and embedded in Durcupan (Fluka, Milan, Italy). Ultrathin
sections (60 nm) were obtained using an Ultracut ultramicrotome
(Reichert Ultracut R; Leika, Wein, Austria) and stained with uranyl
acetate/lead citrate before examination with a CM10 Philips elec-
tron microscope. 
Immunofluorescence staining 
In all experiments, paraffin sections were dewaxed, rehydrated
in a descending scale of ethanols and treated for antigen unmask-
ing and saturation of non-specific sites. Antigen retrieval was per-
formed incubating slides in Na citrate buffer pH 6 either in
microwave at 750 W three times for 3 min (for K10, K16, K17 and
TLR4) or in autoclave at 120°C for 6-10 min (for langerin, filag-
grin, occludin and NFkB). BrdU detection implied DNA denatura-
tion with 2N HCl (30 min), buffering with Na2B4O7 (10 min), and
digestion with 0.05% pepsin in 0.02 M HCl (25 min). The follow-
ing primary antibodies were used for detection and incubated
overnight at 4°C with the exception of monoclonal anti-BrdU
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1:200;
1 h at RT), mouse anti-human keratin 16 (BioSB, dilution 1:100; 1
h at 37°C), and mouse anti-human TLR4 (Novus Biologicals,
Centennial, CO, USA; dilution 1:300; 1 h at 37°C): rabbit anti-
human filaggrin (Sigma-Aldrich; dilution 1:2500); mouse anti-
human keratin 10 (Novus Bio; dilution 1:50); mouse anti-human
keratin 14 (Santa Cruz; dilution 1:100); rabbit anti-human keratin
17 (Sigma-Aldrich; dilution 1:500); rabbit anti-human occludin
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(Sigma-Aldrich; dilution 1:100); mouse anti-human langerin
(Santa Cruz; dilution 1:50); rabbit anti-human NFkB (Santa Cruz;
dilution 1:50). The following secondary antibodies were used 1h at
RT to develop immunofluorescence: Alexa Fluor 488 goat anti-
rabbit IgG (H+L) antibody (dilution 1:100) and goat anti-mouse
FITC-conjugated (dilution 1:200) respectively for anti-K10, anti-
K14, anti-K16, anti-langerin and anti-TLR4 or for anti-filaggrin
and anti-NFkB. One section on each slide was considered as tech-
nical negative control and the primary antibody was thus omitted
and replaced with 0.1 M PBS, pH 7.4. Nuclei were counterstained
with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI
1:50000 dilution in bi-distilled water; 5 min of incubation at RT).
After rinsing in PBS, sections were mounted with Mowiol 4-88
(Sigma-Aldrich). Immunofluorescence analysis were performed
utilizing a Nikon Eclipse E600 equipped with a Nikon digital cam-
era DXM1200 (Nikon, Tokyo, Japan).12 The analysis was aimed at
locating the immunopositivity for the different proteins in the epi-
dermal layers, without any attempts to estimate quantitatively the
possible difference in the staining intensities.
Quantitative analysis of keratinocyte proliferation
For the quantitative analysis of KC proliferation, at least three
immunofluorescence experiments were carried out for each sam-
ple, with two slides per sample and two sections on each slide (12
replicates for each sample). Two independent double-blinded
Figure 1. Epidermal cell proliferation quantitative analysis. A)
Representative BrdU immunofluorescence in normal human skin
paraffin sections. B) Quantitative analysis of keratinocyte prolifera-
tion in skin samples treated with anti-IL-17A, IL-17A, or with
COMBO. Results were expressed as percentage of BrdU-positive cells
per mm2 of living epidermis +1 standard deviation considering
untreated control samples as 100% (thick black line). Single asterisk
indicates a statistically significant difference (P<0.05) vs T24 group.
Double asterisk indicates a statistically significant difference
(P<0.005) vs  T24 group. Triple asterisk indicates a statistically signif-
icant difference (P<0.0001) vs T24 group. (One -way ANOVA test,
Dunnett’s post-test). Dotted white line in A indicates the basal mem-
brane. T24: samples harvested after 24 h of culture; T48, samples har-
vested after 48 h of culture. Scale bar: 20 μm.
Figure 2. Keratin 16 immunofluorescence analysis. Representative photomicrographs of normal human skin paraffin sections after K16
immunofluorescence. A,D) IL-17A inhibitor-treated-samples harvested respectively after 24 (T24) and 48 (T48) h of culture. B,E) IL-
17A-treated-samples harvested respectively after 24 (T24) and 48 (T48) h of culture. C,F) COMBO samples harvested respectively after
24 (T24) and 48 (T48) h of culture. Nuclei are counterstained with DAPI. Dotted white line indicates the basal membrane. Scale bars:
50 µm.
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investigators counted the BrdU-positive cells. The epidermal area
was calculated on adjacent hematoxylin and eosin-stained sec-
tions, excluding the stratum corneum. The software Image-Pro
Plus (version 4.5.019; Media Cybernetics Inc., Silver Spring, MD,
USA) was used for measurement following a previously standard-
ized procedure.12 Results were expressed as the percentage of
BrdU-positive cells per mm2 of living epidermis ± 1 standard devi-
ation, considering untreated control samples as 100%. The statisti-
cally significant differences were obtained after carrying out the
One-way ANOVA test, followed by Dunnett’s post-test.
Quantitative analysis of epidermal LCs
For the quantitative analysis of LCs, at least 3 immunofluores-
cence experiments were carried out in all samples, with two slides
per sample and two sections on each slide (12 replicates for each
sample). Two independent double-blinded investigators counted
the langerin-positive bodies of LCs. Epidermal area was calculated
on adjacent hematoxylin and eosin-stained sections, excluding the
stratum corneum, to normalize the immunofluorescence counts.
For the area measurement the software Image-Pro Plus (version
4.5.019; Media Cybernetics Inc.) has been used following a previ-
ously standardized procedure.10 Results were expressed as percent-
age of LCs/mm2 of living epidermis +1 standard deviation consid-
ering untreated control samples as 100%. The statistically signifi-
cant differences were obtained after carrying out the one-way
ANOVA test, followed by Dunnett’s post-test.
Results
Immunoreactivity after the incubation with the anti-IL-17A
agent was comparable to the observations already published for the
control group concerning K10 and K14,4 K17 and occludin,5 lan-
gerin, filaggrin, and NFkB,13 respectively. Hence, these data refer-
ring to control group are not shown.
Keratinocyte proliferation, K16 and K17 immunofluo-
rescence
BrdU immunostaining was always present as a punctuate stain-
ing in KC nuclei present in the basal layer (Figure 1A). Figure 1B
reports the percentage inhibition of KC proliferation. In accor-
Figure 3. Keratin 17 immunofluorescence analysis. Representative photomicrographs of normal human skin paraffin sections after K17
immunofluorescence. A,D) IL-17A inhibitor-treated-samples harvested respectively after 24 (T24) and 48 (T48) h of culture. B,E) IL-
17A-treated-samples harvested respectively after 24 (T24) and 48 (T48) h of culture. C,F) COMBO harvested respectively after 24 (T24)
and 48 (T48) h of culture. Nuclei are counterstained with DAPI. Dotted white line indicates the basal membrane. White arrow indicates
the discontinuous immunostaining in the granular layer. Scale bars: 50 µm. 
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dance with our previous results,4 IL-17A promptly inhibited cell
proliferation at both time points. After the incubation with the anti-
IL-17A agent, an antiproliferative effect was evident starting from
T24 and, even more, at T48. On the other hand, in COMBO group
cell proliferation raised up only at T24, even though the prolifera-
tion rate levels observed in anti-IL-17A group were never restored.
Although the variability was pronounced within each group, a sta-
tistically significant difference was always observed in all experi-
mental groups at all considered time points.
K16 expression was completely absent in the more differenti-
ated layers (Figure 2) after 24 h of incubation, with some dissimi-
larities regarding the basal and suprabasal compartments among
the three experimental groups. In the IL-17A and the anti-IL-17A
treated groups, a comparable pattern of K16 distribution resulted in
the basal and in the lower spinous layers (Figure 2 A,B).
Unpredictably, in COMBO samples the immunostaining was clear-
ly detectable both in basal and in suprabasal spinous layers (Figure
2C). At T48, the K16 distribution patterns found after the incuba-
tion with the anti-IL-17A agent alone or IL-17A alone were com-
parable with the expression found in the COMBO group at T24,
i.e. in the basal and suprabasal epidermal layers. At T48 the
COMBO group exhibited only a weak immunostaining in the basal
layer (Figure 2F). If present, K17 immunostaining was always
localized in the cytoplasm of the living epidermal compartments.
In anti-IL-17A samples, K17 was never expressed in any epider-
mal layer (Figure 3 A,D). As expected, K17-positive epidermal
cells were evident in IL-17A groups at both time points, with a dif-
ferent distribution pattern at T24 and T48 (Figure 3 B,E, respec-
tively). At T24, a marked K17 immunostaining was detectable in
the most differentiated KCs of the granular layer (Figure 3B). At
T48, the basal layer resulted homogenously immunopositive for
this marker (Figure 3E), while in the granular layer, the immunos-
taining was discontinuous (Figure 3E, white arrow). In the
COMBO group, a weak K17 immunostaining was detectable in the
basal and spinous layers at both time points (Figure 3 C,F).
Terminal differentiation 
In accordance with the literature data, K10 and K14 immuno-
stainings were always localized in the cytoplasm of epidermal ker-
atinocytes in the suprabasal and basal layers, respectively, without
any difference among the experimental groups. The distribution of
both K10 (Figure 4 A-F) and K14 (Figure 4 G-L) was unaffected
by any treatment at all considered time-points. 
Physical epidermal barrier
At T24, in anti-IL-17A group, filaggrin and occludin were con-
tinuously distributed in the KC cytoplasm of the granular layer
(Figure 5 A,D). In IL-17A samples, occludin immunostaining was
weakly detectable and discontinuous (Figure 5E, white arrows). In
parallel, filaggrin immunostaining was less evident when com-
pared with anti-IL-17A group (Figure 5B). In the COMBO group,
filaggrin and occludin were homogeneously localized in the gran-
ular layer, showing a more intense and homogenoeus staining than
in IL-17A group (Figure 5 C,F) and a similar distribution in com-
parison to the anti-IL-17A group (Figure 5 A,D). Since at T48 in
all experimental groups the overall distribution patterns of
Figure 4. Keratin 10 and Keratin 14 immunofluorescence analysis. Representative photomicrographs of normal human skin paraffin
sections after K10 (A-F) and K14 (G-L) immunofluorescence. A,G,D,J) IL-17A inhibitor-treated-samples harvested respectively after
24 (T24) and 48 (T48) h of culture. B,H,E,K) IL-17A -treated-samples harvested respectively after 24 (T24) and 48 (T48) h of culture.
C,I,F,L) COMBO samples harvested respectively after 24 (T24) and 48 (T48) h of culture. Nuclei are counterstained with DAPI. Dotted
white line indicates the basal membrane. Scale bars: 50 µm.
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occludin and filaggrin corresponded at T24 immunostaining, these
data are not shown.
Langerhans cells 
By immunofluorescence, we detected all LCs localized in the
basal and suprabasal layers of epidermis and characterized by a
stellate appearance, due to their dendritic processes originating
from a large cellular body (Figure 6A). The quantitative analysis of
epidermal LCs revealed a statistically significant decrease of LCs’
number at both time points in anti-IL-17A group if compared to
controls (fixed as 100%, thick black line). In IL-17A samples, the
number of LCs started to slightly decrease only after 48 h, con-
firming our previously reported data.9 The incubation with both
agents induced a not statistically different increase of the number
of langerin-positive cells, if compared with IL-17A treated samples
(Figure 6B). 
The ultrastructural analysis helped to investigate LCs’ activa-
tion (Figure 6 C-L). In the group exposed to the specific anti-IL-
17A agent, LCs’ cytoplasm contained scattered Birbeck granules
and there were no morphological signs of activation (Figure 6 C,D)
and this tableau persisted up to 48 h (data not shown). When incu-
bated with IL-17A, LCs always exhibited morphological cytoplas-
mic structures, as abundant Birbeck granules, indicating a clear
activation (Figure 6 F,H, black arrows). 
In the COMBO group, LCs appeared quiescent from a mor-
phological point of view, without any evident sign of phenotype
modification (Figure 6 J,L). Along with LCs features, the enlarge-
ment of intercellular spaces induced by IL-17A incubation (Figure
6 E,G) was greatly reduced after the exposure to the specific anti-
IL-17A agent (Figure 6 I,K). For completing the tableau of the
innate immune epidermal barrier, TLR4 expression was evaluated
by immunofluorescence. No differences were evident among all
the experimental groups regarding TLR4 distribution pattern,
which was confined to the cytoplasm of the epidermal basal layer
(Figure 7). 
Figure 8 reports the immunofluorescence analysis of the localiza-
tion of the transcriptional factor NFkB. In all the experimental sam-
ples, NFkB staining was detectable in the KCs' cytoplasm.
Figure 5. Filaggrin and occludin immunofluorescence analysis. Representative photomicrographs of normal human skin paraffin sec-
tions after filaggrin (A-C) and occludin (D-F) immunofluorescence in samples harvested after 24 h of culture (T24). A,D) IL-17A
inhibitor-treated-samples. B,E) IL-17A -treated-samples. C,F) COMBO samples. Nuclei are counterstained with DAPI. Dotted white
line indicates the basal membrane. White arrows indicate discontinuity of occludin immunofluorescence. Scale bars: 50 µm.
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Figure 6. Epidermal LCs quantitative analysis and ultrastructural analysis. Morphological and quantitative analysis of LCs in samples of
anti-IL-17A, IL-17A or COMBO groups. A) Representative photomicrograph of a normal human skin paraffin section after anti-human-
langerin immunostaining. B) Quantitative analysis of epidermal LCs; results were expressed as percentage of LCs/mm2 of living epidermis
+ 1 standard deviation considering untreated control samples as 100% (thick black line); single asterisk indicates a statistically significant
difference (P<0.05) vs T24 group; double asterisk indicates a statistically significant difference (P<0.005) vs T24 group (One-way ANOVA
test, Dunnett’s post-test). C-L) Representative photomicrographs of normal human skin araldite ultrathin sections. C,D) anti-IL-17A-treat-
ed samples harvested after 24 (T24) h of culture following the overnight incubation. E,F) IL-17A-treated samples harvested after 24 (T24)
h of culture following the overnight incubation. G,H) IL-17A-treated samples harvested after 48 (T48)h of culture following the overnight
incubation; K,L) COMBO samples harvested after 48 (T48) h of culture following the overnight incubation. I,J) COMBO samples har-
vested after 48 (T48) h of culture following the overnight incubation; black arrows indicate Birbeck granules; dotted white line in A indi-
cates the basal membrane. Scale bars: A) 20 μm; C,D,J,L) 2 μm; E,F,G) 5 μm; H) 1 μm; K,I) 10 μm.
[European Journal of Histochemistry 2020; 64:3115] [page 135]
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A clear nuclear localization occurred at T48 in the uppermost
epidermal layers of IL-17A group (Figure 8E, see inset and white
arrows) and in the lower spinous layer of the COMBO group
(Figure 8F, see inset and white arrows), with the exception of the
IL-17A and COMBO groups at T48.
Discussion
In the present study we demonstrate that a specific biological
anti-IL-17A agent, with a well-documented clinical effectiveness,
promptly exerts an anti-psoriatic switch, after the stimulation with
the key psoriatic cytokine IL-17A, in the three-dimensional (3D)
organotypic model of skin culture standardized in our lab.4,5,11-14 Up
to now, most of the data concerning psoriasis and evidences on
therapeutical biological efficacy are obtained during the late phas-
es of psoriasis, leaving the cellular mechanism of the very early
phase of the disease poorly investigated. 
A broad and prompt reversal effect of the epidermal changes
induced by the IL-17A agent is the disappearance of the intercellu-
lar widening induced by IL-17A in our experimental setting. This
observation is parallel to a fine tuning of the expression of the pso-
riatic cytokines K16 and K17. The unaffected K14 and K10 distri-
bution patterns are in agreement with the lack of blistering and
hyperkeratosis, respectively, in all samples at all time points.  
The modulation of the mechanical scaffolding role of cytoplas-
mic intermediate filaments denotes the specific response for the
changing needs of the epidermis coping with a psoriatic stimulus
as IL-17A. We still lack of a conclusive explanation for the specific
K16 distribution in each experimental group, but these results
could be interpreted on the basis of the quantitative analysis of cell
proliferation. In IL-17A samples, where the most relevant inhibi-
tion of epidermal proliferation occurred at both T24 and at T48, the
basal layer always showed a very faint K16 expression. When the
epidermal proliferation partially recovered, as observed after the
incubation with the combination of IL-17A and its specific biolog-
ical agent, the fastest cytoskeletal rearrangement occurs as early as
T24. This proliferative rescue can be interpreted favourably as a
Figure 7. TLR 4 immunofluorescence analysis. Representative photomicrographs of normal human skin paraffin sections after TLR4
immunofluorescence. A,D) IL-17A inhibitor-treated-samples harvested respectively after 24 (T24) and 48 (T48) h of culture. B,E) IL-17A-
treated-samples harvested respectively after 24 (T24) and 48 (T48) h of culture. C,F) COMBO samples harvested respectively after 24 (T24)
and 48 (T48) h of culture. Nuclei are counterstained with DAPI. Dotted white line indicates the basal membrane. Scale bars: 50 µm.
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restraint of the “injury” provoked by IL-17A, as previously
observed in our model.4 This response possibly attenuates the late
epidermal “response to injury”, and, finally, the psoriatic lesion
initiation and progression. Last, but not least, the anti-IL-17A
agent alone is able to induce a partial inhibition of KCs’ prolifera-
tion at T24, and, even more, at T48, thus possessing the highest
proliferative potential and suggesting that this early occurrence has
to become stable at longer time points, as observed in clinics.1,2,15
The expression of occludin and filaggrin, i.e. the proteins con-
stituting the physical barrier of the epidermis, was altered in IL-
17A group. Interestingly, the epidermal barrier was sensitive to
the anti-IL-17A agent as soon as 24 h. Conversely, TLR4 seems
not to be involved in this early epidermal response, thus suggest-
ing a constitutive expression. As a consequence, the reported
NFkB nuclear translocation, indicating its activation, should be
independent by TLR4. Regarding the epidermal innate immunity
mediated by epidermal LCs, the quantitative LCs analysis clearly
shows that the LCs number in living epidermis decreases after the
exposure to the specific anti-IL-17A agent alone if compared to
controls, thus supporting a positive effect on the innate skin
immunity, as this agent does not possess chemoattractant activity.
Moreover, in the COMBO group, however, this number was not
statistically higher than in IL-17A and anti-IL-17A group. A pos-
sible explanation for this phenomenon arises directly from the
ultrastructural analysis. The LCs’ activation signs were strongly
different between the two groups, i.e. IL-17A and COMBO.
Indeed, LC functional activation is a prerequisite for their follow-
ing migration from the epidermal compartment. Considering that
i) IL-17A induces an activation of LCs as shown by numerous
Birbeck granules in the perinuclear area and a condensed chro-
matin;11 and that ii) no clear signs of activation were observed
after the incubation with the anti-IL-17A agent alone, the resulting
effect in the COMBO samples is a trapping of LCs in the epider-
mis. This can be consequent by one side from the chemoattractant
activity attributable to IL-17A and, on the other side, from the lack
of LC activation by the anti-IL-17A agent. 
Figure 8. NFkB immunofluorescence analysis. Representative photomicrographs of normal human skin paraffin sections after NFkB
immunofluorescence. A,D) IL-17A inhibitor-treated-samples harvested respectively after 24 (T24) and 48 (T48) h of culture. B,E) IL-17A-
treated-samples harvested respectively after 24 (T24) and 48 (T48) h of culture. C,F) COMBO samples harvested respectively after 24 (T24)
and 48 (T48) h of culture. Nuclei are counterstained with DAPI. Dotted white line indicates the basal membrane. White arrows in E and
F indicates the nuclear translocation of NFkB. Scale bars: 50 µm.
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As a consequence, LCs are not enabled to leave the epidermis,
resulting more abundant in the COMBO group and persisting also
at T48. Our study describes, for the first time, the most specific
psoriatic cellular events that can be affected or completely reverted
by a specific anti-IL-17A agent, during the very early phases of the
plaques formation and progression within the epidermal compart-
ment. As most of the studies have been carried when psoriasis is a
clinical consolidated skin disease, our experimental approach is
helpful in investigating the very early phase of psoriasis, giving
strong insights to the complex cellular mechanisms between epi-
dermal cells and the soluble factors typical of the psoriatic milieu.
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